Literature DB >> 10591309

Double-blind methylphenidate trials: practical, useful, and highly endorsed by families.

M A Kent1, C S Camfield, P R Camfield.   

Abstract

OBJECTIVE: To evaluate a 3-week, randomized, double-blind, methylphenidate placebo-controlled trial (MPT) in routine practice for children with attention-deficit disorder. PATIENTS AND METHODS: School-aged children with attention-deficit/hyperactivity disorder (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria) who enrolled an "N of 1" trial at a pediatric tertiary care center were eligible. Families (n = 50) with a child eligible for the MPT were given 3 bottles of identical capsules. The capsules contained, in random order: placebo of the prescribed dose of methylphenidate (Ritalin) hydrochloride (0.3 mg/kg or 0.6 mg/kg). Families gave the child 1 capsule at 8 AM and 1 capsule at noon. The family, teacher, and physician were blinded for the order of medication. Conners questionnaires (Conners Parent Questionnaire and Conners Teacher Questionnaire) and written comments were completed by parents and teachers at baseline and at the end of each week. Once MPT results were known and following discussion with the physician, families decided whether to continue methylphenidate therapy. Families were interviewed by telephone 14 to 21 months after the MPT.
RESULTS: Forty-three (86%) of the 50 eligible children (mean age, 129 months) were contacted. No family found the MPT difficult, but 6 trials were incomplete, usually because of side effects. All families used the MPT to decide if methylphenidate was the correct treatment choice for their child and 68% (34 of 50 families) used the results exclusively. The remaining 16 families believed the MPT was helpful. Overall, 31 (72%) of the 43 children had a good response to methylphenidate treatment--20 (47%) continued to use it for longer than 12 months and 8 (26%) for 2 to 12 months; 3 responders chose not to use it after the MPT. Nine of the 43 families chose not to use methylphenidate treatment; however, all indicated that participating in the MPT helped them to make that decision. In follow-up interviews, the same proportion of methylphenidate users and nonusers reported improvement in many areas of function including significantly less time spent doing homework. Users reported reduced aggression (P<.001) and fewer discipline problems (P<.01) compared with nonusers.
CONCLUSIONS: An "N of 1" MPT was easily performed and permitted families to decide whether to use methylphenidate for long-term treatment of attention-deficit disorder or attention-deficit/hyperactivity disorder. Regardless of methylphenidate use or lack of use, the condition of all of these children was improved at follow-up.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10591309     DOI: 10.1001/archpedi.153.12.1292

Source DB:  PubMed          Journal:  Arch Pediatr Adolesc Med        ISSN: 1072-4710


  16 in total

Review 1.  Randomised controlled trials in primary care: scope and application.

Authors:  Aziz Sheikh; Liam Smeeth; Richard Ashcroft
Journal:  Br J Gen Pract       Date:  2002-09       Impact factor: 5.386

2.  Use of double-blind placebo-controlled N-of-1 trials among stimulant-treated youths in The Netherlands: a descriptive study.

Authors:  Adrianne Faber; Ron J Keizer; Paul B van den Berg; Lolkje T W de Jong-van den Berg; Hilde Tobi
Journal:  Eur J Clin Pharmacol       Date:  2006-11-18       Impact factor: 2.953

3.  Using n-of-1 trials as a clinical tool to improve prescribing.

Authors:  C Jane Nikles; Alexandra M Clavarino; Chris B Del Mar
Journal:  Br J Gen Pract       Date:  2005-03       Impact factor: 5.386

4.  The n-of-1 clinical trial: the ultimate strategy for individualizing medicine?

Authors:  Elizabeth O Lillie; Bradley Patay; Joel Diamant; Brian Issell; Eric J Topol; Nicholas J Schork
Journal:  Per Med       Date:  2011-03       Impact factor: 2.512

Review 5.  Promoting productive interactions between parents and physicians in the treatment of children with attention-deficit/hyperactivity disorder.

Authors:  William B Brinkman; Jeffery N Epstein
Journal:  Expert Rev Neurother       Date:  2011-04       Impact factor: 4.618

Review 6.  Current research highlights in child and adolescent psychopharmacology.

Authors:  B Vitiello
Journal:  Curr Psychiatry Rep       Date:  2000-04       Impact factor: 5.285

7.  Efficacy and Safety of Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, and Placebo for Common Psychiatric Disorders Among Children and Adolescents: A Systematic Review and Meta-analysis.

Authors:  Cosima Locher; Helen Koechlin; Sean R Zion; Christoph Werner; Daniel S Pine; Irving Kirsch; Ronald C Kessler; Joe Kossowsky
Journal:  JAMA Psychiatry       Date:  2017-10-01       Impact factor: 21.596

8.  Long-term changes in management following n-of-1 trials of stimulants in attention-deficit/hyperactivity disorder.

Authors:  C Jane Nikles; Geoffrey K Mitchell; Chris B Del Mar; Norma McNairn; Alexandra Clavarino
Journal:  Eur J Clin Pharmacol       Date:  2007-08-16       Impact factor: 2.953

9.  Using stimulant medication for children with ADHD: what do parents say? A brief report.

Authors:  Alice Charach; Anna Skyba; Lisa Cook; Beverley J Antle
Journal:  J Can Acad Child Adolesc Psychiatry       Date:  2006-05

Review 10.  Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD).

Authors:  Ole Jakob Storebø; Erica Ramstad; Helle B Krogh; Trine Danvad Nilausen; Maria Skoog; Mathilde Holmskov; Susanne Rosendal; Camilla Groth; Frederik L Magnusson; Carlos R Moreira-Maia; Donna Gillies; Kirsten Buch Rasmussen; Dorothy Gauci; Morris Zwi; Richard Kirubakaran; Bente Forsbøl; Erik Simonsen; Christian Gluud
Journal:  Cochrane Database Syst Rev       Date:  2015-11-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.